Adolescents’ genetic risks tied to psychotic symptoms

Researchers examine the relationships between neuropsychiatric and cognitive polygenic scores, attention-related phenotypes, and psychosis symptoms.

Glyscend taps CEO to lead oral obesity, type 2 diabetes candidate; Ex-Travecta chief bounces back after company shutdown

As a new wave of type 2 diabetes and obesity drugs takes the industry by storm, Glyscend Therapeutics has tapped a new CEO to lead

September 9, 2023

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder | Psychedelic Invest

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing

May 22, 2024

Gilead, Merck’s experimental long-acting HIV treatment heads to Phase 3

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.